Assessment canadian coorindating health office technology
Assessment canadian coorindating health office technology - steam an error occurred while updating disk io failure
CADTH is a national organization whose stated mission is to provide "Canada’s federal, provincial and territorial health care decision makers with credible, impartial advice and evidence-based information about the effectiveness and cost-effectiveness of drugs and other health technologies".
Some provinces (such as Alberta, British Columbia, Saskatchewan and Quebec) make their drug plans available to all residents who choose to join the plan (Alberta, British Columbia, Saskatchewan) or lack private drug coverage (Quebec).
Feel free to click on the titles of the table in order to sort the content according to your needs or type in any keyword of interest (e.g., Psychiatry) in the search box above the table for a more specific filtering process.
Financing and Assessing Health Care Technology Health care technology is a very broad concept that can be defined as “the set of techniques, drugs, equipment, and procedures used by health care professionals in delivering medical care to individuals and the systems within which such care is delivered.” Although this definition encompasses drugs, this chapter will discuss issues related to “hard” technologies only.
In its Phase Two report, the Committee provided data that showed that, although Canada is the 5 highest among OECD countries in terms of total spending on health care (as a percentage of GDP), it is generally among the bottom third of OECD countries in the availability of health care technology.
For example, Canada ranks 21 out of 17. Data also showed that this technology gap is widening.
Health care technology can improve the speed and accuracy of diagnosis, cure disease, lengthen survival, alleviate pain, facilitate rehabilitation, and maintain independence.
For example, a brief tabled with the Committee by Medical Devices Canada (MEDEC) stated: Modern medical devices and technologies have not only improved the health outcomes for Canadian patients, but by enabling less invasive procedures and shorter hospital stays, have also supported cost-effectiveness in the health care system. However, many concerns were raised during Committee hearings about the availability, financing and assessment of both new and existing health care technologies.He has published seminal papers on the evaluation of genomic assays, clinical utility studies, and on the cost-effectiveness of specific assays.His research is published in leading clinical and policy journals (e.g. degree from the University of Rochester, New York and M. degree in Health Services Research from Stanford University.Over 60 percent of the population lives in the central provinces of Ontario and Quebec, the two largest of the 10 provinces.Canada has Medicare, a universal (publicly funded) healthcare since the 1960s; however, medication, except drugs administered in hospitals and for certain special populations, is not covered through the universal, publicly funded, Medicare program.Journal of the National Cancer Institute, Annals of Internal Medicine, JAMA) and his work is cited in international appraisals of new cancer technologies, such as the UK National Institute of Clinical Excellence and the Canadian Coordinating Office for Health Technology Assessment. Hornberger has provided Chief Medical Officer (CMO) consulting services, contributing to the strategy, development and implementation of innovative clinical programs/study designs that include collaboration with strategic business partners and academic institutes. Hornberger is Adjunct Clinical Professor of Medicine at Stanford University School of Medicine, supervising resident house staff in a clinic devoted to the care of the poor and underserved. He is past Co-Editor of Value in Health and is on the Editorial Board of Medical Decision Making.